Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants

Bone Marrow Transplantation

Volumn 19, Issue 9, 1997, Pages 867-873

  Lindgren, C G ^a   Thompson, J A ^a   Robinson, N ^a   Keeler, T ^a   Gold, P J ^a   Fefer, A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cytokines; Immunotherapy; Interleukin 12; Stem cell transplant

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 2;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHROMIUM 51 RELEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DAUDI CELL; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; PRIORITY JOURNAL; RECIPIENT; STEM CELL TRANSPLANTATION;

EID: 0030962718     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700774     Document Type: Article

References (50)

1. Attal M, Biaise D, Marit G et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995; 86: 1619-1628.
2. Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-647.
3. Petersen FB, Lynch MH, Clift RA et al. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 1993; 11: 1353-1360.
4. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma (see comments). New Engl J Med 1995; 333: 1540-1545.
5. Long GD, Blume KG. Allogeneic bone marrow transplantation for acute myelogenous leukemia. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell: Boston, 1994, pp 607-617.
6. Sanders JE, Flournoy N, Thomas ED et al. Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft vs. host disease. Med Pediatr Oncol 1985; 13: 165-172.
7. Horning SJ, Negrin RS, Chao JC et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2552-2558.
8. Meloni G, Foa R, Vignetti M et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84: 2158-2163.
9. Maraninchi D, Blaise D, Viens P et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991; 78: 2182-2187.
10. Gisselbrecht C, Maraninchi D, Pico JL et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study (see comments). Blood 1994; 83: 2081-2085.
11. Benyunes M, Fefer A. Interleukin-2 in the treatment of hematologic malignancies. In: Atkins M, Mier J (eds). Therapeutic Applications of Interleukin-2. Marcel Dekker: New York, 1993, pp 163-175.
12. Benyunes MC, Higuchi C, York A et al. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995; 16: 283-288.
13. Fefer A, Benyunes MC, York A et al. Use of interleukin-2 after bone marrow transplantation. In: Champlin R, Gale RP (eds). Advances and Controversies in Bone Marrow Transplantation. Bone Marrow Transplantation: Keystone, Colorado, 1995, 15 (Suppl. 1), pp S162-S166.
14. Fefer A, Robinson N, Benyunes MC et al. Interleukin-2 (IL-2) after autologous blood or marrow transplantation. In: Dicke KA, Keating A (eds). Proceedings of the Eighth International Symposium on Autologous Marrow and Blood Transplantation. Carden Jennings Publishing Company Ltd: Charlottesville, VA, 1996 (in press).
15. Soiffer RJ, Murray C, Gonin R et al. Effect of low-dose Interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994; 84: 964-971.
16. Robinson N, Sanders JE, Benyunes MC et al. Phase I trial of Interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 1996; 87: 1249-1254.
17. Robinson N, Benyunes MC, Thompson JA et al. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study. Bone Marrow Transplant 1997; 19: 435-442.
18. Weisdorf DJ, Anderson PM, Blazar BR et al. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia - a phase I study. Transplantation 1993; 55: 61-66.
19. Klingemann HG, Eaves CJ, Barnett MJ et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 1994; 14: 389-396.
20. Trinchieri G, Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008-4027.
21. Gately MK, Wolitzky AG, Quinn PM et al. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992; 143: 127-142.
22. Naume B, Gately M, Espevik T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol 1992; 148: 2429-2436.
23. Zeh HJ III, Hurd S, Storkus WJ et al. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother 1993; 14: 155-161.
24. Rossi AR, Pericle F, Rashleigh S et al. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994; 83: 1323-1328.
25. Wong EK, Eaves C, Klingemann H-G. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12. Bone Marrow Transplant 1996; 18: 63-71.
26. DeBlaker-Hohe DF, Yamauchi A, Yu CR et al. IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Immunol 1995; 165: 33-43.
27. Wu C-Y, Warrier RR, Carvajal DM et al. Biological function and distribution of human interleukin-12 receptor β chain. Eur J Immunol 1996; 26: 345-350.
28. Chizzonite R, Truitt T, Desai BB et al. IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J Immunol 1992; 148: 3117-3124.
29. Desai BB, Quinn PM, Wolitzky AG et al. IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol 1992; 148: 3125-3132.
30. Brunda MJ, Luistro L, Warrier RR et al. Antitumor and anti-metastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223-1230.
31. Mu J, Zou JP, Yamamoto N et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 1995; 55: 4404-4408.
32. Sykes M, Szot GL, Nguyen PL et al. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995; 86: 2429-2438.
33. Soiffer RJ, Robertson MJ, Murray C et al. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 1993; 82: 2790-2796.
34. Higuchi CM, Thompson JA, Cox T et al. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 1989; 49: 5509-5513.
35. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. New Engl J Med 1979; 300: 1068-1073.
36. Fefer A. Graft-versus-tumor responses: adoptive cellular therapy in bone marrow transplantation. In: Forman S, Thomas ED, Blume KG (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Cambridge, MA, 1994, pp 231-241.
37. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
38. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
39. Neubauer MA, Benyunes MC, Thompson JA et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1994; 13: 311-316.
40. Reittie JE, Gottlieb D, Heslop HE et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351-1358.
41. Biaise D, Olive D, Stoppa AM et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092-1097.
42. Higuchi CM, Thompson JA, Petersen FB et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561-2568.
43. Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170: 827-845.
44. Gately MK, Desai BB, Wolitzky AG et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991; 147: 874-882.
45. Papa MZ, Vetto JT, Ettinghausen SE et al. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res 1986; 46: 5618-5623.
46. McVicar DW, Merchant RE, Merchant LH et al. Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro. Cancer Immunol Immunother 1989; 29: 211-218.
47. Grimm EA, Muul LM, Wilson DJ. The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL. Transplantation 1985; 39: 537-540.
48. Allavena P, Paganin C, Zhou D et al. Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. Blood 1994; 84: 2261-2268.
49. Reed JC, Abidi AH, Alpers JD et al. Effect of cyclosporin A and dexamethasone on Interleukin-2 receptor gene expression. J Immunol 1986; 137: 150-154.
50. Presky DH, Yang H, Minetti LJ et al. A functional Interleukin-12 receptor complex is composed of two β type cytokine receptor subunits. Proc Natl Acad Sci USA 1996; 93: 14002-14007.